MDM2 and sarcoma: Few FDC sarcoma cases with aberrant phenotype have been reported before including a case of intra-abdominal FDC sarcoma with pleomorphic features and aberrant expression of neuroendocrine markers [11], an unusual case of FDC sarcoma of the omentum with pleomorphic morphology and aberrant cytokeratin expression [12], another case with aberrant T-cell antigen expression [13], and a clinicopathologic study of 15 FDC cases with expression of MDM2, somatostatin receptor 2A, and PD-L1 [14].